O. Delgado Sánchez

[Reconciliation errors at admission and departure in old and polymedicated patients. Prospective, multicenter randomized study].

O. Delgado Sánchez, J. Nicolás Picó, I. Martínez López, 2009, Medicina clinica.

Comparison of commercial 5-aminolevulinic acid (Gliolan®) and the pharmacy-compounded solution fluorescence in glioblastoma

Ruth Villalonga-Planells, P. Villalonga, O. Delgado Sánchez, 2019, Acta Neurochirurgica.

[Study of drug dose calculation for morbidly obese patients].

O. Delgado Sánchez, G. Serra Soler, N. Galán Ramos, 2009, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.

Impact of a multidisciplinary team for the management of thrombotic microangiopathy

O. Delgado Sánchez, J. Lumbreras, L. Pallarés Ferreres, 2018, PloS one.

Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis

L. Puig, O. Delgado Sánchez, J. C. Carrascosa Carrillo, 2022, Expert review of pharmacoeconomics & outcomes research.

Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation

O. Delgado Sánchez, Á. Hidalgo-Vega, J. C. Carrascosa Carrillo, 2022, Acta dermato-venereologica.

[Voriconazole-associated phototoxicity].

O. Delgado Sánchez, G. Serra Soler, I. Martinez-Lopez, 2006, Farmacia Hospitalaria.

The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain

O. Delgado Sánchez, Á. Hidalgo-Vega, M. Merino, 2023, Frontiers in Public Health.

An international comparative analysis and roadmap to sustainable biosimilar markets

S. Simoens, G. Castañeda-Hernández, G. Werutsky, 2023, Frontiers in Pharmacology.

Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients

O. Delgado Sánchez, L. Bento, A. Gutiérrez, 2019, ClinicoEconomics and outcomes research : CEOR.